Bristol-Myers Squibb | BMY - Operating Profit


Bristol-Myers Squibb reported $255M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Abbott USD 1.36B 775M Sep/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Drreddys Laboratories INR 12.81B 11.98B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
J&J USD 6.47B 1B Sep/2026
Medtronic USD 1.84B 254M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Perrigo USD 27.2M 3.7M Sep/2026
Pfizer USD 662M 5M Sep/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Sanofi EUR 2.38B 115M Jun/2026
United Therapeutics USD 241.3M 89.5M Sep/2026
Zoetis USD 1.03B 88M Sep/2026